Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Prevent Osteoporotic Fractures with a Fracture Liaison Service

Micah Yu, MD, Anna Lafian, DO, & Christina Downey, MD  |  Issue: May 2019  |  May 18, 2019

System Challenges

Diagnosing osteoporosis and getting patients to believe in and commit to a treatment plan pose many challenges. Many patients do not believe they have suffered a fracture due to osteoporosis and place the blame entirely on the low level of trauma that preceded the fracture. In the care of medically complex patients, precious clinic time is often diverted toward seemingly more pressing health conditions, such as diabetes, hypertension and cardiovascular disease. The beauty of an FLS is the diagnosis is already made; patients who suffer an osteoporotic fracture need osteoporosis treatment.

James Larsen, MD, a geriatrician at LLUH, laments over the issue of non-
adherence. He notes that at our institution, “there is no problem getting patients screened for osteoporosis; the problem is getting patients committed to treatment. Patients are worried about the side effects of treatment.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

His concerns echo studies showing that since 2002 a decline in prescribing rates for bisphosphonates has corresponded with a profound increase in fragility fractures among women.9 The risks of atypical femur fractures and osteonecrosis of the jaw with the use of bisphosphonates have been overly emphasized by the media, drowning out the loss of independence, infection and mortality that can follow immobility from fractures.

There is hope. The National Osteoporosis Foundation (NOF) has played an instrumental part in fighting osteoporosis nationally by providing education to health professionals and the general public. In addition to raising awareness of the scope of the problem, the NOF takes a stand to help eliminate it by providing health professionals training and certification in Fracture Liaison Services. The NOF also offers guidance on diagnostic assessment, monitoring and pharmacologic treatment in its Clinician’s Guide for Treatment of Osteoporosis, published and updated since 1999.4

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

At Loma Linda University Health System, the FLS improves the rates of screening and diagnosis prior to a fracture, decreases the incidence of refracture and increases awareness of the consequences of osteo­porosis among patients and primary care physicians. The goal is to bring the national average for appropriate post-fracture osteoporosis management to the level of breast cancer screening and beta blocker treatment after a myocardial infarction.

Imagine that.


Micah Yu, MDMicah Yu, MD, is a rheumatology fellow at Loma Linda University, Calif.

Anna Lafian, DOAnna Lafian, DO, is a rheumatology fellow at Loma Linda University, Calif.

Christina Downey, MD, RhMSUS, CCDChristina Downey, MD, RhMSUS, CCD, is an assistant professor of medicine in the Division of Rheumatology at Loma Linda University, Calif.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:FracturesOsteoporosisosteoporosis treatmentsosteoporotic fracture rates

Related Articles

    Unexpected Benefits of Bisphosphonates after Hip Fracture

    February 3, 2012

    Recent trials show this bisphosphonates can reduce subsequent hip fractures and mortality, while remaining cost effective.

    Osteoporosis Experts Discuss Bisphosphonate Holidays

    November 24, 2020

    ACR CONVERGENCE 2020—Bisphosphonates are an important treatment for millions of older Americans with osteoporosis because the drugs inhibit osteoclastic bone resorption to reduce the risk of painful, debilitating fractures.1 More than 20 years ago, data emerged that bisphosphonates have a long terminal half-life.2 So after years of therapy, could some patients take a drug holiday?…

    Build Up Bone

    June 1, 2007

    Current management of osteoporosis

    Reading Rheum

    May 1, 2009

    Handpicked Reviews of Contemporary Literature

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences